A recent study from the “Department of Microbiology and Immunology, University of California, San Francisco, California, USA; and Howard Hughes Medical Institute, University of California, San Francisco, California, USA” shows that Loss of signalling via Gα13 in germinal centre B-cell-derived cancer. This study was published in the 28 September 2014 issue of the journal “Nature ” (I.F:42) by Prof Cyster JG, Muppidi JR and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for B-cell-derived cancers: BMP2 suppresses the expression of G protein alpha-13 (GNA13) and inhibits the progression of B-cell-derived cancers via up regulation of its target gene
Significance:
This study suggests a molecular therapy for human leukaemia: BMP2, by increasing the expression of its target gene, it may inhibit the expression of G protein alpha-13 (GNA13). Thus, pharmacological formulations encompassing “BMP2 activators” may be used to inhibit B-cell-derived cancers.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for B-cell-derived cancers: BMP2 suppresses the expression of G protein alpha-13 (GNA13) and inhibits the progression of B-cell-derived cancers via up regulation of its target gene, 23/April/2014, 06.46 am,Genome-2-Bio-MedicineDiscoverycenter (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How BMP2 inhibits the expression of G protein alpha-13 (GNA13).
